Emergent Biosolutions EBS Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's financing cash flow?
- Emergent Biosolutions (EBS) reported financing cash flow of -$11.4M in Q1 2026.
- How has Emergent Biosolutions's financing cash flow changed year-over-year?
- Emergent Biosolutions's financing cash flow decreased by 2750.0% year-over-year, from -$400K to -$11.4M.
- What is the long-term trend for Emergent Biosolutions's financing cash flow?
- Over 4 years (2021 to 2025), Emergent Biosolutions's financing cash flow has grown at a -0.8% compound annual growth rate (CAGR), from -$141M to -$136.6M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.